Maxillo-Facial Surgery Division, University Hospital of Parma, Parma, Italy.
Maxillo-Facial Surgery Division, University Hospital of Parma, Parma, Italy.
J Craniomaxillofac Surg. 2020 May;48(5):514-520. doi: 10.1016/j.jcms.2020.02.010. Epub 2020 Feb 24.
To compare the most important techniques usually used in these patients.
A multicentric retrospective evaluation on patients treated for cT1/2 N0 OTFOM SCC was conducted; patients in group A were treated by transoral approach and miomucosal local flap while those in group B were treated by pull-through and free flap reconstruction. Oncologic, functional and quality of life evaluation was assessed.
55 patients were enrolled. Group A consisted of 35 patients and group B 20. At the 3-year follow-up 30 and 17 patients in group A and B were alive without disease. Tongue mobility index score was 23.3 in group A and 13.89 in group B (p < .001); Sydney swallowing mean score was 118.5 and 543.22 in group A and B (p < .001). EORTC QLC-C30 was of 33.57 in group A and 38.89 in group B (p = 0.057).
T1/T2 cancers of the tongue and floor of the mouth can be equally treated with both techniques. Because of the fact that transoral resection with buccinators reconstruction provides better functional outcome, this technique should be preferred whenever appropriate.
比较这些患者中常用的最重要技术。
对经口途径治疗 cT1/2 N0 OTFOM SCC 的患者进行了多中心回顾性评估；A 组患者接受经口入路和黏膜局部瓣治疗，B 组患者接受经口拉出和游离皮瓣重建治疗。评估了肿瘤学、功能和生活质量。
共纳入 55 例患者。A 组 35 例，B 组 20 例。在 3 年随访时，A 组和 B 组各有 30 例和 17 例患者无病存活。A 组的舌运动指数评分为 23.3，B 组为 13.89（p<0.001）；A 组和 B 组的悉尼吞咽平均评分为 118.5 和 543.22（p<0.001）。A 组的 EORTC QLC-C30 为 33.57，B 组为 38.89（p=0.057）。
舌和口底的 T1/T2 癌症可以用这两种技术同等治疗。由于经口切除和颊肌重建提供了更好的功能结果，因此只要合适，应优先选择这种技术。
